Gautier Jean-Charles, Gury Thierry, Guffroy Magali, Masson Régis, Khan-Malek Richard, Hoffman David, Pettit Syril, Harpur Ernie
Sanofi R&D, Paris, France
Sanofi R&D, Paris, France.
Toxicol Pathol. 2014 Oct;42(7):1105-16. doi: 10.1177/0192623314524489. Epub 2014 Apr 9.
Differences were examined between male and female Sprague-Dawley rats in the response of 16 urinary biomarkers (measured using several assay platforms) to renal injury produced by gentamicin administered subcutaneously for 10 days at a dosage of 75 mg/kg. Urinary biomarkers expressed as fold difference from contemporaneous controls and renal histopathology were assessed after 3 and 10 doses. On day 4, minimal proximal tubular changes were observed microscopically in all males but no females; on day 11, more extensive and more severe injury was observed to a similar extent in all animals of both sexes. Modest increases (maximum 5-fold) in all urinary biomarkers (except epidermal growth factor [EGF], which was decreased) on day 4 and marked elevations (maximum 271-fold) on day 11 were seen consistently in both sexes. However, the magnitude of the increases differed between the sexes. On day 4, despite the lack of tubular injury, many biomarkers were more elevated in females than males but this rarely led to statistically significant sex differences; only 2 biomarkers (β2-microglobulin and total protein) showed a greater increase in males than females in line with the histopathology. On day 11, there were many more biomarkers that showed a statistically significant difference between the sexes in fold change with treatment; in line with the results on day 4, the majority of biomarkers were more increased in females than males. It remains unresolved if sex differences in the magnitude of biomarker response at injury threshold would lead to any difference in diagnostic interpretation between the sexes. These data highlight the need for publication of more studies using animals of both sexes to fully explore the influence of sex on the diagnostic performance of the novel biomarkers.
研究了雄性和雌性Sprague-Dawley大鼠对16种尿液生物标志物(使用多种检测平台测量)的反应差异,这些生物标志物是针对皮下注射庆大霉素10天(剂量为75mg/kg)所导致的肾损伤。在给予3剂和10剂后,评估了以与同期对照的倍数差异表示的尿液生物标志物和肾脏组织病理学。在第4天,在所有雄性大鼠中显微镜下观察到轻微的近端肾小管变化,但雌性大鼠未观察到;在第11天,在两性所有动物中均观察到了程度相似的更广泛、更严重的损伤。在第4天,所有尿液生物标志物(表皮生长因子[EGF]除外,其呈下降趋势)均有适度升高(最大为5倍),在第11天两性均一致出现显著升高(最大为271倍)。然而,升高的幅度在两性之间存在差异。在第4天,尽管没有肾小管损伤,但许多生物标志物在雌性中的升高幅度大于雄性,但这很少导致具有统计学意义的性别差异;只有2种生物标志物(β2-微球蛋白和总蛋白)根据组织病理学显示在雄性中的升高幅度大于雌性。在第11天,有更多的生物标志物在治疗后的倍数变化上显示出两性之间具有统计学意义的差异;与第4天的结果一致,大多数生物标志物在雌性中的升高幅度大于雄性。损伤阈值时生物标志物反应幅度的性别差异是否会导致两性在诊断解读上的任何差异仍未得到解决。这些数据凸显了需要发表更多使用两性动物的研究,以充分探索性别对新型生物标志物诊断性能的影响。